Wearable Injectors Market

Wearable Injectors Market by Product Type(On-Body and Off-Body), Therapy (Immuno-oncology, Diabetes, Cardiovascular diseases), Technology(Spring-based, Motor Driven, Rotary Pump, Expanding Battery), Care Setting (Hospitals) - Global Forecast to 2026

Report Code: MD 6659 Jul, 2021, by marketsandmarkets.com

[193 Pages Report] The global wearable injectors market is projected to reach USD 11.5 billion by 2026 from USD 7.2 billion in 2021, at a CAGR of 9.9% during the forecast period. Growth in this market is mainly driven by factors such as the shift of healthcare delivery toward homecare due to COVID-19, advantages of wearable injectors in the administration of various drugs, the rising prevalence of chronic diseases (such as cancer, diabetes, and CVD), favorable reimbursement scenario in major markets, and technological advancements in injector devices. However, the preference for alternative drug delivery modes, high costs, and a poor reimbursement structure in developing countries are expected to limit the adoption of wearable injectors to a certain extent.

Wearable Injectors Market

To know about the assumptions considered for the study, Request for Free Sample Report

Covid-19 Impact on the wearable injectors Market

The COVID-19 pandemic is expected to have a positive impact on the wearable injectors market. In response to COVID-19, there has been a reorientation of medical priorities across healthcare institutions, with treatment for COVID-19 patients being the utmost priority. This has impacted the growth of the wearable injectors market. Wearable injectors represent a meaningful platform to bridge the gap between autoinjectors and in-clinic care.

Wearable injectors are expected to fill important gaps in healthcare infrastructure and connected health services. Currently, a rise in chronic ailments stemming from COVID-19 morbidity will partially fuel growth in the adoption of wearable injectors as patients with chronic pulmonary, cardiovascular, and neurological conditions begin to manage the long-term effects of the disease. Patients with chronic diseases are demanding a shift from clinic to at-home drug delivery to protect themselves from COVID-19 exposure in clinics.

Also, with the increased understanding that conditions like immune deficiency disorders result in not only vaccine resistance but also predispose patients to prolonged illness due to COVID-19, patients are exercising more caution. Infused therapies account for USD 35 billion in the specialty drugs market. It is estimated that shifting these treatments from hospitals or clinics to home care may confer 30–70% cost savings for both patients and healthcare payers. Wearable injector solutions are particularly well-suited for infusion therapies, as the pumps are designed to deliver large doses over minutes, and even hours; biologics and high viscosity drugs, including chemotherapy, monoclonal antibodies, and drugs targeted to auto-immune, blood, and genetic disorders, are commonly combined with wearable injector devices to support patient care at home and as an alternative to in-clinic care.

Wearable injectors Market Dynamics

Driver: Shift of healthcare delivery toward homecare due to COVID-19

The uncertainty caused by the COVID-19 pandemic has influenced the demand for different therapies and wearable drug delivery devices. To avoid the spread of the infection and protect high-risk patients from getting infected, healthcare systems across the globe undertook measures to postpone treatments for various diseases such as cancer. At the onset of the pandemic, the risks for patients receiving care increased. Also, hospitals, where a majority of patients receive treatments, became high-risk centers during the pandemic. In an effort to counter these challenges and provide effective care to patients suffering from various diseases, there has been a shift from hospital-based care to home-based care.

In the UK, NHS England rolled out a program permitting convenient, non-hospital-based treatments for cancer patients due to the COVID-19 pandemic. The adoption of wearable injectors for the delivery of oncology drugs and other maintenance therapies currently undergoing clinical trials has gained prominence during this pandemic.

As a result of the pandemic,  there is an increased acceptance of telehealth and homecare. This has driven a shift in healthcare delivery from hospitals/clinics to home care settings. This is expected to create significant growth opportunities for market players in the coming years.

Opportunity: Increasing demand for biologics and mAbs

A growing focus on the use of biologics and mAbs to treat diseases such as rheumatoid arthritis, cardiovascular disease, and cancer will provide significant growth opportunities for wearable injectors, as these drugs need to be administered via the parenteral route (intravenous, subcutaneous, or intramuscular delivery). According to PhRMA (Pharmaceutical Research and Manufacturers of America), as many as 907 biologics were in development in 2013; the number of biologic drugs in development is continuing to increase exponentially, with more than 2,700 remedies in development as of mid-2017, triple the 907 in development in 2013. mAb-based biotherapies account for 50% of the top 100 drugs and are projected to maintain a dominant position in the pharmaceutical market.

Challenge: Unfavorable reimbursement structure in developing countries

A number of developing countries do not offer reimbursement for wearable injectors. For instance, in India, wearable insulin pumps are not reimbursed, and no specific guidelines regarding their use are given on prescription. In China, patients with Type 1 diabetes have to bear the entire cost of insulin pumps and supplies out-of-pocket. The lack of reimbursement directly affects access to and the adoption of wearable injectors and is thus expected to negatively impact the growth of the market in the coming years.

The on-body injectors holds the largest share in wearable injectors market by type, in the forecast period

The on-body accounted for the largest share in the forecast year. The large share of this segment can be attributed to the patients ease to deliver a precise amount of drug to the body over a controlled period of time.

The spring-based technology segment accounted for the largest share in the forecast period. The large share of this segment can be attributed to the rising demand for adhesive patches, as these devices are user-friendly and enable patients to accurately deliver the required drug subcutaneously.

The diabetes segment accounted for the largest share in the forecast period. The large share of this segment can be attributed to The high burden of diabetes across the globe, coupled with the growing availability of wearable injectors for the treatment of these diseases, is driving the growth of this market segment

The hospitals and clinics segment accounted for a larger market share during the forecast period. The large share of this segment can primarily be attributed to the rising preference for the self-administration of medication and the increasing need to curb healthcare costs. In addition, the growing demand for technologically developed drug delivery approaches, which lower the hospitalization rate and require minimal expertise, is expected to boost the growth of the home healthcare settings segment.

North America accounted for the largest share of the global wearable injectors market., by region in the forecast period.

North America accounted for the largest share of the global wearable injectors market. The large share of North America in this market is due to the rising prevalence of chronic and lifestyle-related diseases and the presence of advanced healthcare infrastructure in the region.

Wearable Injectors Market by Region

Key Market Players

Key players in the Wearable injectors market: Becton, Dickinson and Company(US), Ypsomed (Switzerland), Amgen (US), Subcuject (Denmark), Enable Injections (US), Medtronic plc (Ireland), Insulet Corporation (US), United Therapeutics Corp. (US), CeQur SA (Switzerland), Sensile Medical (Switzerland), SteadyMed Therapeutics (US), ATS Automation (Canada), West Pharmaceutical Services, Inc. (US), Unilife Corporation (UK), Tandem Diabetes Care (US), Valeritas (US), Bühler Motor (Switzerland), Sonceboz (Switzerland), Noble (US), Elcam Drug Delivery Devices (Israel), Bespak Europe Ltd. (UK), Stevanato Group (Italy), Sorrel Medical (Israel), Weibel CDS AG (Switzerland), and Neuma (US).

Scope of the report

Report Metric

Details

Market Size available for years

2019-2026

Base Year Considered

2020

Forecast period

2021-2026

Forecast Unit

Value (USD Billion)

Segments covered

Wearable injectors Market:
Type, Technology, Therapy and End User

Geographies covered

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
  • Middle East & Africa

Companies Covered

Becton, Dickinson and Company(US), Ypsomed(Switzerland), Amgen(US), Subcuject(Denmark), Enable Injections(US), Medtronic Plc(Ireland), Insulet Corporation(US), United Therapeutics Corp (Us), CeQur SA(Switzerland), Sensile Medical(Switzerland), Steadymed Therapeutics (US), ATS Automation(Canada), West Pharmaceutical Services, Inc(US), Unilife Corporation(UK), Tandem Diabetes Care(US), Valeritas(US), Bühler Motor(Switzerland), Sonceboz(Switzerland), Noble(US), Elcam Drug Delivery Device(Israel), Bespak (UK), Stevanato Group(Italy), Sorrel Medical(Israel), Weibel CDS AG(Switzerland) and Neuma(US).

The research report categorizes the market into the following segments:

Wearable Injectors Market, By Type

  • On-body Injector
  • Off-body Injector

Wearable Injectors Market, By Technology

  • Spring Based
  • Motor Based
  • Rotary pump
  • Expanding battery
  • Other technology

Wearable Injectors Market, By Therapy

  • Immuno-oncology
  • Diabetes
  • Cardiovascular disease
  • Other disease

Wearable Injectors Market, By End User

  • Hospitals and clinics
  • Home healthcare setting

Wearable Injectors Market, by Region

  • North America North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
  • Middle East & Africa

Recent Developments:

PRODUCT LAUNCHES


Month & Year

COMPANY Name

APPROACH

Segment

Product

April 2021

Medtronic (Ireland)

Product Launch

Diabetes

Infusion Set that can be worn up to seven days

February 2021

United Therapeutics (US)

Product Launch

Cardiovascular

Received FDA approval for its Remunity Disposable Subcutaneous Pump

January  2021

Insulet Corporation (US)

Product Launch

Diabetes

New Omnipod DASH Insulin Management System

June 2020

Medtronic (Ireland)

Product Launch

Diabetes

MiniMed 780G

June 2018

Insulet Corporation (US)

FDA Approval

Diabetes

Omnipod DASH Insulin Management System

DEALS


Month & Year

Deal Type

Company 1

Company 2

Description

April 2021

Acquisition

Amgen (US)

Five Prime Therapeutics (US)

This acquisition—for USD 38.00 per share in cash—was focused on developing immuno-oncology and targeted cancer therapies.

March 2021

Partnership

Aptar and Noble International (US)

Dne Pharma (Norway)

Aptar Pharma’s Unidose Liquid System will be used by Dne Pharma as part of a broad patient onboarding and awareness program for Ventizolve.

February 2021

Collaboration

Subcuject (Denmark)

Philips-Medisize (US)

This collaboration was focused on the development, manufacturing, and commercialization of Subcuject WBI.

September 2020

Collaboration

Ypsomed
(Switzerland)

SCHOTT and Lonza
(Switzerland)

The three companies are developing a comprehensive solution for wearable patch injectors for the subcutaneous self-injection of large volumes of liquid formulations.

May 2020

Partnership

Ypsomed (Switzerland)

Dexcom (US)

This partnership was focused on the development of a hybrid closed-loop system.

OTHER DEVELOPMENTS

MONTH & Year

TYPE OF DEVELOPMENT

COMPANY NAME

DESCRIPTION

September  2020

Expansion

Insulet Corporation (US)

The company expanded its presence in Sweden, Finland, Norway, and Denmark.

March 2018

Expansion

Ypsomed (Switzerland)

Ypsomed established its first subsidiary in Canada.

March 2018

Expansion

Enable Injections (US)

The company planned to employ an arcuately expandable elastomer bladder and injection cannula system.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 18)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
                    FIGURE 1 WEARABLE INJECTORS MARKET SEGMENTATION
                    FIGURE 2 WEARABLE INJECTORS MARKET, BY REGION
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
           TABLE 1 STANDARD CURRENCY CONVERSION RATES
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 23)
    2.1 RESEARCH DATA
           FIGURE 3 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
           FIGURE 4 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
           FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (WEARABLE INJECTORS MARKET)
           FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
           FIGURE 7 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
           FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: AMGEN INC.
           FIGURE 9 SUPPLY-SIDE MARKET SIZE ESTIMATION: WEARABLE INJECTORS MARKET (2020)
           FIGURE 10 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FOR THE WEARABLE INJECTORS MARKET (2021-2026)
           FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           FIGURE 12 BOTTOM-UP APPROACH
           FIGURE 13 TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
           FIGURE 14 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET RANKING ESTIMATION
    2.5 ASSUMPTIONS FOR THE STUDY
    2.6 RISK ASSESSMENT
    2.7 COVID-19 HEALTH ASSESSMENT
    2.8 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE WEARABLE INJECTORS MARKET
           FIGURE 15 WEARABLE INJECTORS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
           FIGURE 16 WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
           FIGURE 17 WEARABLE INJECTORS MARKET, BY THERAPY, 2021 VS. 2026 (USD MILLION)
           FIGURE 18 WEARABLE INJECTORS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
           FIGURE 19 GEOGRAPHIC SNAPSHOT OF THE WEARABLE INJECTORS MARKET

3 EXECUTIVE SUMMARY (Page No. - 38)

4 PREMIUM INSIGHTS (Page No. - 43)
    4.1 WEARABLE INJECTORS MARKET OVERVIEW
           FIGURE 20 SHIFT OF HEALTHCARE DELIVERY TOWARD HOMECARE DUE TO COVID-19 IS DRIVING MARKET GROWTH
    4.2 NORTH AMERICAN WEARABLE INJECTORS MARKET, BY COUNTRY AND THERAPY
           FIGURE 21 DIABETES SEGMENT COMMANDED THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2020
    4.3 WEARABLE INJECTORS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 22 MARKET IN CHINA TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
    4.4 WEARABLE INJECTORS MARKET: REGIONAL MIX
           FIGURE 23 NORTH AMERICA IS THE LARGEST MARKET FOR WEARABLE INJECTORS

5 MARKET OVERVIEW (Page No. - 47)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 24 WEARABLE INJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Shift of healthcare delivery toward homecare due to COVID-19
                    5.2.1.2 Advantages of wearable injectors in the administration of various drugs
                    5.2.1.3 Growing prevalence of chronic diseases
                    5.2.1.4 Favorable reimbursement scenario in major markets
                    5.2.1.5 Technological advancements and design development
           5.2.2 RESTRAINTS
                    5.2.2.1 Preference for alternative drug delivery modes
                    5.2.2.2 High cost of wearable injectors
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increasing demand for biologics and mAbs
                               FIGURE 25 US: BIOLOGIC MEDICINES IN DEVELOPMENT, 2017
           5.2.4 CHALLENGES
                    5.2.4.1 Unfavorable reimbursement structure in developing countries

6 INDUSTRY INSIGHTS (Page No. - 52)
    6.1 TECHNOLOGY ANALYSIS
    6.2 PRICING ANALYSIS
           TABLE 2 AVERAGE SELLING PRICE: WEARABLE INJECTORS
    6.3 VALUE CHAIN ANALYSIS
           FIGURE 26 WEARABLE INJECTORS MARKET: VALUE CHAIN ANALYSIS
    6.4 ECOSYSTEM MARKET MAP
           FIGURE 27 WEARABLE INJECTORS MARKET: ECOSYSTEM MARKET MAP
    6.5 SUPPLY CHAIN ANALYSIS
           FIGURE 28 WEARABLE INJECTORS MARKET: SUPPLY CHAIN ANALYSIS
    6.6 PORTER’S FIVE FORCES ANALYSIS
           FIGURE 29 PORTER’S FIVE FORCES ANALYSIS (2020): WEARABLE INJECTORS MARKET
           TABLE 3 WEARABLE INJECTORS MARKET: PORTER’S FIVE FORCES ANALYSIS
           6.6.1 THREAT OF NEW ENTRANTS
                    6.6.1.1 Growth in the overall wearable injectors market
                    6.6.1.2 Growing consolidation
                    6.6.1.3 Poor financing environment
           6.6.2 THREAT OF SUBSTITUTES
           6.6.3 BARGAINING POWER OF SUPPLIERS
           6.6.4 BARGAINING POWER OF BUYERS
           6.6.5 INTENSITY OF COMPETITIVE RIVALRY
    6.7 REGULATORY ANALYSIS
    6.8 PATENT ANALYSIS
           6.8.1 PATENT PUBLICATION TRENDS FOR WEARABLE INJECTORS
                    FIGURE 30 GLOBAL PATENT PUBLICATION TRENDS (2015–2020)
    6.9 IMPACT OF COVID-19 ON THE WEARABLE INJECTORS MARKET

7 WEARABLE INJECTORS MARKET, BY TYPE (Page No. - 62)
    7.1 INTRODUCTION
           TABLE 4 WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
    7.2 ON-BODY INJECTORS
           7.2.1 ON-BODY INJECTORS SEGMENT DOMINATED THE MARKET IN 2020
                    TABLE 5 ON-BODY WEARABLE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.3 OFF-BODY INJECTORS
           7.3.1 OFF-BODY INJECTORS SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
                    TABLE 6 OFF-BODY WEARABLE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

8 WEARABLE INJECTORS MARKET, BY TECHNOLOGY (Page No. - 66)
    8.1 INTRODUCTION
           TABLE 7 WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
    8.2 SPRING-BASED TECHNOLOGY
           8.2.1 SPRING-BASED TECHNOLOGY ENABLES THE DELIVERY OF DRUGS WITH HIGHER VOLUME AND VISCOSITY
                    TABLE 8 WEARABLE INJECTORS MARKET FOR SPRING-BASED TECHNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
    8.3 MOTOR-DRIVEN TECHNOLOGY
           8.3.1 THESE DEVICES CAN GENERATE HIGH FORCE FOR SUBCUTANEOUS INJECTIONS OF HIGH-VISCOSITY LIQUIDS
                    TABLE 9 WEARABLE INJECTORS MARKET FOR MOTOR-DRIVEN TECHNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
    8.4 ROTARY PUMP TECHNOLOGY
           8.4.1 THESE DEVICES SHOW HIGH PRECISION AND THE POSSIBILITY TO NOT ALTER THE FLUID PROPERTIES
                    TABLE 10 WEARABLE INJECTORS MARKET FOR ROTARY PUMP TECHNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
    8.5 EXPANDING BATTERY TECHNOLOGY
           8.5.1 EXPANDING BATTERY TECHNOLOGY SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
                    TABLE 11 WEARABLE INJECTORS MARKET FOR EXPANDING BATTERY TECHNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
    8.6 OTHER TECHNOLOGIES
           TABLE 12 WEARABLE INJECTORS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2019–2026 (USD MILLION)

9 WEARABLE INJECTORS MARKET, BY THERAPY (Page No. - 73)
    9.1 INTRODUCTION
           TABLE 13 WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
    9.2 DIABETES
           9.2.1 HIGH PREVALENCE OF DIABETES ACROSS THE GLOBE TO DRIVE THE GROWTH OF THIS MARKET SEGMENT
                    TABLE 14 INSULIN DEVICES AVAILABLE FOR DIABETES PATIENTS
                    TABLE 15 WEARABLE INJECTORS MARKET FOR DIABETES, BY COUNTRY, 2019–2026 (USD MILLION)
    9.3 IMMUNO-ONCOLOGY
           9.3.1 IMMUNO-ONCOLOGY SEGMENT TO WITNESS NEGATIVE GROWTH DURING THE FORECAST PERIOD
                    TABLE 16 WEARABLE INJECTORS MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
    9.4 CARDIOVASCULAR DISEASES
           9.4.1 CARDIOVASCULAR DISEASES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
                    TABLE 17 WEARABLE INJECTORS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
    9.5 OTHER THERAPIES
           TABLE 18 WEARABLE INJECTORS MARKET FOR OTHER THERAPIES, BY COUNTRY, 2019–2026 (USD MILLION)

10 WEARABLE INJECTORS MARKET, BY END USER (Page No. - 80)
     10.1 INTRODUCTION
             TABLE 19 WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.2 HOSPITALS AND CLINICS
             10.2.1 HOSPITALS AND CLINICS ARE THE LARGEST END USERS OF WEARABLE INJECTORS
                        TABLE 20 WEARABLE INJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2019–2026 (USD MILLION)
     10.3 HOME HEALTHCARE SETTINGS
             10.3.1 HOME HEALTHCARE SETTINGS SEGMENT TO WITNESS HIGHER GROWTH DURING THE FORECAST PERIOD
                        TABLE 21 WEARABLE INJECTORS MARKET FOR HOME HEALTHCARE SETTINGS, BY COUNTRY, 2019–2026 (USD MILLION)

11 WEARABLE INJECTORS MARKET, BY REGION (Page No. - 84)
     11.1 INTRODUCTION
             FIGURE 31 WEARABLE INJECTORS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
             TABLE 22 WEARABLE INJECTORS MARKET, BY REGION, 2019–2026 (USD MILLION)
     11.2 NORTH AMERICA
             FIGURE 32 NORTH AMERICA: WEARABLE INJECTORS MARKET SNAPSHOT
             TABLE 23 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY COUNTRY,2019–2026 (USD MILLION)
             TABLE 24 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 25 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
             TABLE 26 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
             TABLE 27 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.2.1 US
                        11.2.1.1 Growing IV infusion expenditure is a key factor driving the US market.
                                     TABLE 28 US: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 29 US: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 30 US: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 31 US: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.2.2 CANADA
                        11.2.2.1 Rising prevalence of chronic diseases in Canada to drive the demand for drugs that can be self-administered
                                     TABLE 32 CANADA: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 33 CANADA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 34 CANADA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 35 CANADA: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.3 EUROPE
             FIGURE 33 EUROPE: WEARABLE INJECTORS MARKET SNAPSHOT
             TABLE 36 EUROPE: WEARABLE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 37 EUROPE: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 38 EUROPE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
             TABLE 39 EUROPE: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
             TABLE 40 EUROPE: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.1 GERMANY
                        11.3.1.1 Availability of government support for drug development and approval to drive growth in the German wearable injectors market
                                     TABLE 41 GERMANY: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 42 GERMANY: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 43 GERMANY: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 44 GERMANY: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.2 UK
                        11.3.2.1 Government focus on biosimilar innovation to drive the market growth
                                     TABLE 45 UK: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 46 UK: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 47 UK: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 48 UK: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.3 FRANCE
                        11.3.3.1 100% coverage for diabetes by SHI to drive market growth in France
                                     TABLE 49 FRANCE: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 50 FRANCE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 51 FRANCE: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 52 FRANCE: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.4 REST OF EUROPE
                        TABLE 53 ROE: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 54 ROE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                        TABLE 55 ROE: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                        TABLE 56 ROE: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.4 ASIA PACIFIC
             TABLE 57 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 58 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 59 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
             TABLE 60 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
             TABLE 61 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.1 JAPAN
                        11.4.1.1 Large number of patients suffering from diabetes, CVD, and other chronic conditions to drive market growth in Japan
                                     TABLE 62 JAPAN: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 63 JAPAN: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 64 JAPAN: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 65 JAPAN: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.2 CHINA
                        11.4.2.1 Large diabetic population to drive market growth in China
                                     TABLE 66 CHINA: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 67 CHINA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 68 CHINA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 69 CHINA: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 Large diabetic population to drive the market for wearable injectors in India
                                     TABLE 70 INDIA: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 71 INDIA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 72 INDIA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 73 INDIA: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.4 REST OF ASIA PACIFIC
                        TABLE 74 ROAPAC: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 75 ROAPAC: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                        TABLE 76 ROAPAC: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                        TABLE 77 ROAPAC: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.5 LATIN AMERICA
             11.5.1 INCREASING PREVALENCE OF DIABETES AND OTHER CHRONIC CONDITIONS TO DRIVE THE MARKET IN LATIN AMERICA
                        TABLE 78 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 79 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                        TABLE 80 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                        TABLE 81 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.6 MIDDLE EAST & AFRICA
             11.6.1 DEMAND FOR WEARABLE INJECTORS IN THE MANAGEMENT OF DIABETES AND CVD IS EXPECTED TO INCREASE IN THE MIDDLE EAST AND AFRICA
                        TABLE 82 CONFERENCES IN THE MIDDLE EAST AND AFRICA (2016–2018)
                        TABLE 83 MIDDLE EAST AND AFRICA: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 84 MIDDLE EAST AND AFRICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                        TABLE 85 MIDDLE EAST AND AFRICA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                        TABLE 86 MIDDLE EAST AND AFRICA: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 125)
     12.1 INTRODUCTION
             FIGURE 34 KEY MARKET DEVELOPMENTS (JANUARY 2018 TO JULY 2021)
     12.2 REVENUE ANALYSIS OF KEY MARKET PLAYERS
             FIGURE 35 REVENUE ANALYSIS OF THE KEY PLAYERS OPERATING IN THE WEARABLE INJECTORS MARKET
     12.3 MARKET SHARE ANALYSIS
             FIGURE 36 WEARABLE INJECTORS MARKET SHARE, BY KEY PLAYER, 2020
     12.4 COMPETITIVE SCENARIO
             12.4.1 PRODUCT LAUNCHES
                        TABLE 87 WEARABLE INJECTORS MARKET: PRODUCT LAUNCHES  (JANUARY 2018 TO JULY 2021)
             12.4.2 DEALS
                        TABLE 88 WEARABLE INJECTORS MARKET: DEALS (JANUARY 2018 TO JULY 2021)
             12.4.3 OTHER DEVELOPMENTS
                        TABLE 89 WEARABLE INJECTORS MARKET: OTHER DEVELOPMENTS (JANUARY 2018 TO JULY 2021)
     12.5 COMPETITIVE BENCHMARKING
     12.6 COMPANY EVALUATION MATRIX
             12.6.1 STARS
             12.6.2 EMERGING LEADERS
             12.6.3 PERVASIVE PLAYERS
             12.6.4 EMERGING COMPANIES
                        FIGURE 37 WEARABLE INJECTORS MARKET: GLOBAL COMPANY EVALUATION MATRIX
     12.7 COMPETITIVE LEADERSHIP MAPPING (SMES/START-UPS)
             12.7.1 PROGRESSIVE COMPANIES
             12.7.2 STARTING BLOCKS
             12.7.3 RESPONSIVE COMPANIES
             12.7.4 DYNAMIC COMPANIES
                        FIGURE 38 WEARABLE INJECTORS MARKET: COMPANY EVALUATION MATRIX FOR SMES/START-UPS

13 COMPANY PROFILES (Page No. - 140)
     13.1 KEY PLAYERS
(Business Overview, Products, Key Insights, Recent Developments, MnM View)* 
             13.1.1 AMGEN INC.
                        TABLE 90 AMGEN INC.: BUSINESS OVERVIEW
                        FIGURE 39 AMGEN INC.: COMPANY SNAPSHOT (2020)
             13.1.2 MEDTRONIC PLC
                        TABLE 91 MEDTRONIC PLC: BUSINESS OVERVIEW
                        FIGURE 40 MEDTRONIC PLC: COMPANY SNAPSHOT (2020)
             13.1.3 INSULET CORPORATION
                        TABLE 92 INSULET CORPORATION: BUSINESS OVERVIEW
                        FIGURE 41 INSULET CORPORATION: COMPANY SNAPSHOT (2020)
             13.1.4 BECTON, DICKINSON AND COMPANY
                        TABLE 93 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
                        FIGURE 42 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
             13.1.5 YPSOMED
                        TABLE 94 YPSOMED: BUSINESS OVERVIEW
                        FIGURE 43 YPSOMED: COMPANY SNAPSHOT (2020)
             13.1.6 UNITED THERAPEUTICS CORPORATION
                        TABLE 95 UNITED THERAPEUTICS CORPORATION: BUSINESS OVERVIEW
                        FIGURE 44 UNITED THERAPEUTICS CORPORATION: COMPANY SNAPSHOT (2020)
             13.1.7 SUBCUJECT
                        TABLE 96 SUBCUJECT: BUSINESS OVERVIEW
             13.1.8 ENABLE INJECTIONS
                        TABLE 97 ENABLE INJECTIONS: BUSINESS OVERVIEW
             13.1.9 CEQUR SA
                        TABLE 98 CEQUR SA: BUSINESS OVERVIEW
             13.1.10 SENSILE MEDICAL (A PART OF GERRESHEIMER)
                        TABLE 99 SENSILE MEDICAL: BUSINESS OVERVIEW
     13.2 OTHER PLAYERS
             13.2.1 STEADYMED THERAPEUTICS
                        TABLE 100 STEADYMED THERAPEUTICS: BUSINESS OVERVIEW
             13.2.2 ATS AUTOMATION
                        TABLE 101 ATS AUTOMATION: BUSINESS OVERVIEW
                        FIGURE 45 ATS AUTOMATION: COMPANY SNAPSHOT (2020)
             13.2.3 WEST PHARMACEUTICAL SERVICES, INC.
                        TABLE 102 WEST PHARMACEUTICAL SERVICES, INC.: BUSINESS OVERVIEW
                        FIGURE 46 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2020)
             13.2.4 UNILIFE CORPORATION
                        TABLE 103 UNILIFE CORPORATION: BUSINESS OVERVIEW
             13.2.5 TANDEM DIABETES CARE
                        TABLE 104 TANDEM DIABETES CARE: BUSINESS OVERVIEW
                        FIGURE 47 TANDEM DIABETES CARE: COMPANY SNAPSHOT (2020)
             13.2.6 VALERITAS, INC.
                        TABLE 105 VALERITAS, INC.: BUSINESS OVERVIEW
                        FIGURE 48 VALERITAS, INC.: COMPANY SNAPSHOT (2020)
             13.2.7 BÜHLER MOTOR GMBH
                        TABLE 106 BÜHLER MOTOR GMBH: BUSINESS OVERVIEW
                        FIGURE 49 BÜHLER MOTOR GMBH: COMPANY SNAPSHOT (2020)
             13.2.8 SONCEBOZ
                        TABLE 107 SONCEBOZ: BUSINESS OVERVIEW
             13.2.9 NOBLE INTERNATIONAL LLC (AN APTAR PHARMA COMPANY)
                        TABLE 108 NOBLE INTERNATIONAL LLC: BUSINESS OVERVIEW
                        FIGURE 50 NOBLE INTERNATIONAL LLC: COMPANY SNAPSHOT (2020)
             13.2.10 ELCAM DRUG DELIVERY DEVICES (E3D)
                        TABLE 109 ELCAM DRUG DELIVERY DEVICES: BUSINESS OVERVIEW
             13.2.11 BESPAK EUROPE LTD.
                        TABLE 110 BESPAK EUROPE LTD.: BUSINESS OVERVIEW
                        FIGURE 51 BESPAK EUROPE LTD.: COMPANY SNAPSHOT (2020)
             13.2.12 STEVANATO GROUP
                        TABLE 111 STEVANATO GROUP: BUSINESS OVERVIEW
             13.2.13 SORREL MEDICAL
                        TABLE 112 SORREL MEDICAL: BUSINESS OVERVIEW
             13.2.14 WEIBEL CDS
                        TABLE 113 WEIBEL CDS: BUSINESS OVERVIEW
             13.2.15 NEUMA LLC
                        TABLE 114 NEUMA: BUSINESS OVERVIEW
*Details on Business Overview, Products, Key Insights, Recent Developments, MnM View might not be captured in case of unlisted companies. 

14 APPENDIX (Page No. - 187)
     14.1 DISCUSSION GUIDE
     14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     14.3 AVAILABLE CUSTOMIZATIONS
     14.4 RELATED REPORTS
     14.5 AUTHOR DETAILS

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Business, Factiva, and D&B Hoovers), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the wearable injectors market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The wearable injectors market comprises several stakeholders such as wearable injector manufacturers and distributors and regulatory organizations. The demand side of this market is characterized by hospitals & clinics, and home healthcare setting.

Various primary sources from both, the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.
Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents for wearable injectors market is provided below:

Wearable Injectors Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by type, by technology, by therapy, by end user, and by region).

Data Triangulation

After arriving at the market size, the total wearable injectors market was divided into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation, and market breakdown procedures were employed, wherever applicable.

Objectives of the Study

  • To define, describe, analyze, and forecast the size of the wearable injectors market on the basis of type, technology, therapy, end user and region.
  • To provide detailed information on the major factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges)
  • To strategically analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To forecast the size of the market segments with respect to North America, Europe, Asia Pacific, latin America and Middle East and Africa.
  • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies.
  • To track and analyze competitive developments such as product launches, partnerships, acquisitions and other developments in the market.
  • To benchmark players within the wearable injectors market using the Competitive Leadership Mapping framework which analyzes market players on various parameters within the broad categories of business and product strategy.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players

Geographic Analysis

  • Further breakdown of the Rest of Asia Pacific wearable injectors market into South Korea, New Zealand, and other countries.
COVID-19

Get in-depth analysis of the COVID-19 impact on the Wearable Injectors Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Wearable Injectors Market

Request For Special Pricing
Report Code
MD 6659
Published ON
Jul, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Wearable Injectors Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home